Madrigal Pharmaceuticals Reports Fourth-Quarter and Full-Year 2025 Financial Results
Madrigal Pharmaceuticals(US:MDGL) Globenewswire·2026-02-19 12:00Fourth-quarter and full-year 2025 Rezdiffra® (resmetirom) net sales of $321.1 million and $958.4 million, respectively As of year-end 2025, more than 36,250 patients on Rezdiffra Built industry-leading MASH pipeline with more than 10 programs at multiple stages of developmentReports cash, cash equivalents, restricted cash and marketable securities of $988.6 million as of Dec. 31, 2025Company to host conference call today, Feb. 19, 2026, at 8 a.m. EST CONSHOHOCKEN, Pa., Feb. 19, 2026 (GLOBE NEWSWIRE) -- Madr ...